These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34080519)

  • 1. Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant
    Wei X; Zhao M; Xiao X
    J Chemother; 2021 Dec; 33(8):547-553. PubMed ID: 34080519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin, teicoplanin, daptomycin, and linezolid MIC creep in methicillin-resistant Staphylococcus aureus is associated with clonality.
    Hsieh YC; Lin YC; Huang YC
    Medicine (Baltimore); 2016 Oct; 95(41):e5060. PubMed ID: 27741120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
    Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
    Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
    Lawson W; Nathwani D; Eckmann C; Corman S; Stephens J; Solem C; Macahilig C; Li J; Baillon-Plot N; Charbonneau C; Haider S
    Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S40-6. PubMed ID: 26206621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; MacGowan AP
    J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of daptomycin & linezolid against methicillin resistant Staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in Central India.
    Chitnis S; Katara G; Hemvani N; Pareek S; Chitnis DS
    Indian J Med Res; 2013 Jan; 137(1):191-6. PubMed ID: 23481072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.
    Canut A; Isla A; Betriu C; Gascón AR
    Eur J Clin Microbiol Infect Dis; 2012 Sep; 31(9):2227-35. PubMed ID: 22371294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
    Housman ST; Sutherland CA; Nicolau DP
    Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation.
    Olney KB; Howard JI; Burgess DS
    J Clin Pharmacol; 2024 Jul; 64(7):860-865. PubMed ID: 38497326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
    Patel N; Lubanski P; Ferro S; Bonafede M; Harrington S; Evans A; Stellrecht K; Lodise TP
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5141-4. PubMed ID: 19805558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model.
    Luther MK; LaPlante KL
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7790-4. PubMed ID: 26369963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
    Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
    Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Molecular Epidemiology and Reduced Susceptibility to Glycopeptides and Daptomycin on Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Lee HY; Chen CL; Liu SY; Yan YS; Chang CJ; Chiu CH
    PLoS One; 2015; 10(8):e0136171. PubMed ID: 26295150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation.
    Wei XC; Zhao MF; Li X; Xiao X
    J Clin Pharmacol; 2020 Jun; 60(6):768-774. PubMed ID: 32080861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Garrigós C; Murillo O; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Ariza J
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5251-6. PubMed ID: 20921321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
    Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH
    Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.